SonALAsense is a clinical stage company developing sonodynamic therapy (SDT), a first-in-class noninvasive drug-device combination to treat brain cancers and other solid tumors. SDT uses an MRI-guided focused ultrasound device together with a drug called SONALA-001 (proprietary intravenous aminolevulinic acid), which selectively targets tumor cells. We have two ongoing Phase 2 clinical trials for recurrent glioblastoma (rGBM) and diffuse intrinsic pontine glioma (DIPG). Both trials are currently recruiting (rGBM: NCT05370508 and DIPG: NCT05123534).